Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Receivables - Net (2023 - 2025)

Historic Receivables - Net for BioLineRx (BLRX) over the last 3 years, with Q2 2025 value amounting to $78000.0.

  • BioLineRx's Receivables - Net fell 9754.64% to $78000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $78000.0, marking a year-over-year decrease of 9754.64%. This contributed to the annual value of $2.5 million for FY2024, which is 59162.01% up from last year.
  • BioLineRx's Receivables - Net amounted to $78000.0 in Q2 2025, which was down 9754.64% from $1.5 million recorded in Q1 2025.
  • BioLineRx's 5-year Receivables - Net high stood at $3.6 million for Q3 2024, and its period low was $78000.0 during Q2 2025.
  • Over the past 3 years, BioLineRx's median Receivables - Net value was $2.5 million (recorded in 2024), while the average stood at $2.0 million.
  • Per our database at Business Quant, BioLineRx's Receivables - Net surged by 59162.01% in 2024 and then crashed by 9754.64% in 2025.
  • Quarter analysis of 3 years shows BioLineRx's Receivables - Net stood at $358000.0 in 2023, then soared by 591.62% to $2.5 million in 2024, then plummeted by 96.85% to $78000.0 in 2025.
  • Its Receivables - Net stands at $78000.0 for Q2 2025, versus $1.5 million for Q1 2025 and $2.5 million for Q4 2024.